Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE

Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE

Purpose: Recent reports personalizing the administered activity (AA) of each cycle of peptide receptor radionuclide therapy based on the predicted absorbed dose (AD) to the kidneys (dose-limiting organ) have been promising. Assuming identical renal pharmacokinetics for each cycle is pragmatic, howev...

Full description

Bibliographic Details
Main Authors: Aldridge, M.D (Author), Falzone, N. (Author), Gains, J.E (Author), Gaze, M.N (Author), Lee, B.Q (Author), Malcolm, J.C (Author), Mirando, D. (Author), Vallis, K.A (Author)
Format: Article
Language:English
Published: Springer Science and Business Media Deutschland GmbH 2022
Subjects:
[177Lu]Lu-DOTATATE
Article
body weight
child
clinical article
controlled study
dose response
dosimetry
Dosimetry
drug absorption
drug clearance
drug dose escalation
drug dose regimen
drug tumor level
drug uptake
female
follow up
human
Inter-cyclic changes
kidney
liver
male
multiple cycle treatment
neuroblastoma
Neuroblastoma
organs at risk
oxodotreotide lutetium lu 177
Peptide receptor radionuclide therapy
pharmacokinetic assay
Pharmacokinetics
prediction
preschool child
radiation absorption
radiation dose escalation
radiation dose response
radiosensitivity
school child
simulation
single photon emission computed tomography-computed tomography
spleen
treatment outcome
treatment response
tumor volume
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items